EP. 1: How Ponatinib Factors into the Treatment of a Type of Leukemia
December 23rd 2022
Kendra Sweet, MD, discussed results of the the phase 2 OPTIC trial, which investigated ponatinib in a group of patients with resistant, chronic phase chronic myeloid leukemia.